Stammdaten
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Evofem Biosciences, Inc. |
|---|---|
| Ticker | EVFM |
| CIK | 0001618835 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,1 Mio. USD |
| Beta | -1,29 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 20,183,000 | 391,000 | 0.00 | 20,274,000 | -74,336,000 |
| 2025-09-30 | 10-Q | 4,952,000 | -1,569,000 | -0.01 | 13,807,000 | -75,066,000 |
| 2025-06-30 | 10-Q | 4,825,000 | -1,784,000 | -0.02 | 14,382,000 | -69,616,000 |
| 2025-03-31 | 10-Q | 845,000 | 956,000 | 0.00 | 12,877,000 | -69,587,000 |
| 2024-12-31 | 10-K | 19,363,000 | -8,860,000 | -0.11 | 23,789,000 | -71,257,000 |
| 2024-09-30 | 10-Q | 4,496,000 | -2,365,000 | -0.02 | 23,942,000 | -70,888,000 |
| 2024-06-30 | 10-Q | 4,160,000 | 1,351,000 | 0.00 | 8,551,000 | -69,315,000 |
| 2024-03-31 | 10-Q | 3,603,000 | -4,809,000 | -0.16 | 8,217,000 | -70,666,000 |
| 2023-12-31 | 10-K | 18,218,000 | 52,979,000 | 0.05 | 10,554,000 | -66,510,000 |
| 2023-10-31 | 10-Q | 100,000,000 | ||||
| 2023-09-30 | 10-Q | 5,112,000 | 66,005,000 | 0.10 | 13,322,000 | -56,359,000 |
| 2023-06-30 | 10-Q | 2,458,000 | -8,558,000 | -5.43 | 14,074,000 | -55,664,000 |
| 2023-03-31 | 10-Q | 5,809,000 | -2,354,000 | -1.85 | 26,034,000 | -56,401,000 |
| 2022-12-31 | 10-K | 16,837,000 | -76,698,000 | -167.42 | 25,163,000 | -71,800,000 |
| 2022-09-30 | 10-Q | 6,371,000 | 89,506,000 | -4.39 | 42,283,000 | -78,044,000 |
| 2022-06-30 | 10-Q | 6,034,000 | -125,980,000 | -580.48 | 53,474,000 | -215,995,000 |
| 2022-03-31 | 10-Q | 4,251,000 | -31,888,000 | -2.88 | 34,571,000 | -128,100,000 |
| 2021-12-31 | 10-K | 8,244,000 | -205,192,000 | -23.63 | 42,512,000 | -104,315,000 |
| 2021-09-30 | 10-Q | 1,712,000 | -74,061,000 | -7.20 | 67,427,000 | -58,827,000 |
| 2021-06-30 | 10-Q | 1,857,000 | -33,426,000 | -4.01 | 108,748,000 | 8,964,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.